724787-12-6

Basic information

• Product Name: 3-chloro-6-Methoxy-[1,5]-naphthyridin-4-ol
• Synonyms: 3-chloro-6-Methoxy-[1,5]-naphthyridin-4-ol
• CAS NO: 724787-12-6
• Molecular Formula: C9H7ClN2O2
• Molecular Weight: 211
• Mol File: 724787-12-6.mol

Chemical Properties

• Boiling Point: 331.5±37.0 °C(Predicted)
• Appearance: /
• Density: 1.458±0.06 g/cm3(Predicted)
• PKA: 0.84±0.50(Predicted)
• CAS DataBase Reference: 3-chloro-6-Methoxy-[1,5]-naphthyridin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-chloro-6-Methoxy-[1,5]-naphthyridin-4-ol(724787-12-6)
• EPA Substance Registry System: 3-chloro-6-Methoxy-[1,5]-naphthyridin-4-ol(724787-12-6)

Safety Data

• Hazardous Substances Data: 724787-12-6(Hazardous Substances Data)

Upstream product

• 23443-25-6 6-methoxy-1,5-naphthyridin-4-ol 
• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 25063-69-8 5-[[(6-methoxypyridin-3-yl)amino]methylidene]-2,2-dimethyl-1,3-dioxane-4,6-dione 

Downstream Products

• 915976-85-1 8-bromo-7-chloro-2-methoxy-1,5-naphthyridine 
• 943025-80-7 methyl [3-chloro-6-(methyloxy)-1,5-naphthyridin-4-yl]acetate 
• 943025-84-1 [(4R/S)-(3-chloro-4-hydroxy-7-oxo-4,5-dihydro-7H-pyrrolo[3,2,1-de]-1,5-naphthyridin-4-yl)]methyl 4-methylbenzenesulfonate 

Relevant articles and documents

SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR

Provided are a preparation and applications of a six-membered fused with six-membered heterocyclic compound, specifically, provided in the present invention is a compound as represented by formula I as follows, where the definitions of the groups are as described in the description. The compound has TRK kinase inhibiting activity and can serve as a pharmaceutical composition for treating TRK dysfunction-related diseases.

ANTI-BACTERIAL HETEROCYCLIC COMPOUNDS AND THEIR SYNTHESIS

The compounds of Formula I and Formula (B) are described herein along with their stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms, and pharmaceutically active

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

SUBSTITUTED 1-METHYL-1H-QUINOLIN-2-ONES AND 1-METHYL-1H-1,5-NAPHTHYRIDIN-2-ONES AS ANTIBACTERIALS

Bicyclic nitrogen containing compounds of formula (I) and their use as antibacterials.

AMINOPIPERIDINE QUINOLINES AND THEIR AZAISOSTERIC ANALOGUES WITH ANTIBACTERIAL ACTIVITY

The present invention relates to compounds that demonstrate antibacterial activity, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans. In particular this invention relates to compounds useful for the treatment of bacterial infections in warm-blooded animals such as humans, more particularly to the use of these compounds in the manufacture of medicaments for use in the treatment of bacterial infections in warm blooded animals such as humans.

NOVEL COMPOUNDS HAVING AN ANTI-BACTERIAL ACTIVITY

The present invention describes novel anti-bacterial compounds of formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.